Castle Biosciences, Inc.CSTLNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank75
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
3.30%
↑ 117% vs avg
Percentile
P75
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-18.98%
Historical baseline
PeriodValueYoY Change
20253.30%-71.3%
202411.48%+156.1%
2023-20.49%+51.9%
2022-42.57%-9.4%
2021-38.91%-243.6%
2020-11.32%-157.1%
201919.82%+220.0%
2018-16.51%+78.2%
2017-75.61%-